Click amount to donate direct to CounterPunch
  • $25
  • $50
  • $100
  • $500
  • $other
  • use PayPal
Keep CounterPunch ad free. Support our annual fund drive today!

The Return of FrankenSalmon


The genetically engineered AquAdvantage salmon, (AAS), often referred to as a “Frankenfish”, is moving through the FDA approval process despite doubts raised at 2010 hearings, in scientific reports and by 400,000 consumers.

The genetically modified salmon, created by Boston-based AquaBounty Technologies, is created to grow twice as fast as wild Atlantic salmon–reaching its full size in 18 months instead of three years. It was created by inserting the coding sequence from a Chinook salmon growth hormone gene under the control of an “antifreeze protein promoter and terminator” from ocean pout into wild Atlantic salmon. No wonder it’s called a Frankenfish.

Ninety-five to 99 percent of AAS are sterile, said AquaBounty at FDA hearings in 2010, so they are unlikely to breed and threaten wild salmon stocks if they escape. (If they did breed, though, it could Jurassic Park-like since AAS eat five times more food than wild salmon and have less fear of predators, according to background materials.) Nor is 1 to 5 percent a small amount considering the 15 million eggs AquaBounty plans to grow: that could amount to 750,000 fertile fish.

To prevent such risks, AquaBounty told an FDA advisory committee it plans to grow the eggs at a facility on Prince Edward Island in Canada, where escapees could not survive. “Water from the facility, including effluent from all floor drains, fish tanks and egg incubators, eventually discharges” into a tidal river that flows into the Gulf of Lawrence, says the AquAdvantage FDA briefing package. Because water temperatures in the winter months are very low and the water has a high salinity, “it is highly unlikely that early life stages of any Atlantic salmon at the facility would be able to survive if they were able to escape.”

But escape into the Gulf of Lawrence is not the only risk. AquaBounty also has safety plans for the adult salmon, which it plans to grow out and slaughter in the country of Panama because that environment  is also hostile to survival. “In the lower reaches of the watershed, the water temperature is in the range of 26 to 28 degrees C, at or near the upper incipient lethal level for Atlantic salmon,” says the FDA report. “As a result, it is extremely unlikely that AquAdvantage Salmon would ever be able to survive and migrate to the Pacific Ocean.”

In the FDA briefing report, AquAdvantage salmon were also found to have high incidences of “jaw erosion” and “focal inflammation” (infection), though the defects are said to be “of low magnitude and not likely to be debilitating to fish in a production setting.” What about the people who eat them? The report also identified low glucose
levels and a possible “increase in the level of IGF-1 [insulin-like growth factor-1] in the AquAdvantage salmon compared to sponsor control fish.”

Perhaps most troubling at the FDA hearings was AquaBounty’s policy for handling dead fish in Panama. In its Environmental Assessment report, it says, “As dead fish are deposited, they will be covered with caustic lime, followed by another layer of dead fish and caustic lime, and so on, until the burial pit is ~0.5 m deep, at which point it will [be] sealed with plastic and covered with soil. Successive pits will be located at a minimum distance of 0.5–1.0 m from those used previously; the aggregate collection of such pits will be located on high ground that is not within the 100-year flood plain. . . . In the event that disposal capacity at the site is inadequate to handle the immediate or aggregate waste volume, alternative means of disposal will be sought.” Why are so many fish expected to die?

More Concerns

There are also questions about the GE fish’s allergic potential. When FDA food scientists Kathleen Jones and Kevin Greenlees presented AquaBounty’s AquAdvantage salmon allergy studies at 2010 hearings, members on the committee considering the approval were appalled at the “science.”

How can safety be determined for levels of allergens when a number that would “unsafe” has not been determined asked members of the Veterinary Medicine Advisory Committee. It’s as if  “you selected a particular allergen in goat meat and another allergen that was in sheep meat and you compared the two and you found a significant difference but both of them were at irrelevantly low numbers,” said Louisiana State University’s David F. Senior, who chaired the committee. “Who cares?”  Other members berated the low numbers of fish used in studies, the inclusion of irrelevant fish in studies which “diluted out the power of the study,” and the generally bad science.

And not only were the studies low powered, some having only six or seven fish in them, there were errors in studies! James D. McKean, with the Department of Veterinary Diagnostic and Production Animal Medicine at Iowa State University, noted there were six “controls” in Table 15 and “in Table 16, there are 7. And I am still unclear as to where that extra sample came from?”

“Nothing reliable can be gained from this study,” said Craig Altier, DVM, from the College of Veterinary Medicine at Cornell University about other data presented, calling the work a “real mess.” This “is an important thing to study and the experiment was a bust, why hasn’t it been done again?”

The briefing packet even says the FDA an not determine if the AquAdvantage salmon would cause more allergies than other fish because excessive culling of “abnormal” salmon and other “technical flaws” in AquaBounty’s study so “skewed” data as to “limit its interpretation that we cannot rely on its results”!  What? Why are so many fish expected to be flawed–and why is approval even considered?

The briefing report also identified low glucose levels in the fish and a possible “increase in the level of IGF-1 [insulin-like growth factor-1] in the AquAdvantage salmon compared to sponsor control fish.”  IGF-1 is linked to cancer and early puberty and its presence in rBGH-created milk was what made the product so controversial. Government scientists have said that IGF-1 is destroyed by digestion or pasteurization, but other scientists disagree.

And there are other concerns besides the AquAdvantage salmon’s allergic potential and levels of its IGF-1. While supporters claim the fast growing fish would supply desirable omega oils,  according to Michael Hansen, PhD, senior scientist with Consumers Union, “in terms of the ratio of omega-3 to omega-6 fatty acids, GE salmon fare worse than wild fish and slightly worse than farmed salmon.”

Finally, there are Jurassic Park-like questions that persist with all genetically modified organisms. The FDA briefing packet discloses an unexpected and unwanted coding “rearrangement” in AquAdvantage salmon in which the original inserted genetic material has moved from “the far upstream promoter regions” to a “downstream location relative to the growth hormone coding region.”  Why.

Despite its documented aberrations, the AquAdvantage salmon will likely not even be  labeled in more evidence that the FDA puts industry before consumers.

Martha Rosenberg’s is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

2016 Fund Drive
Smart. Fierce. Uncompromised. Support CounterPunch Now!

  • cp-store
  • donate paypal

CounterPunch Magazine


Weekend Edition
October 28, 2016
Friday - Sunday
John Pilger
Inside the Invisible Government; War, Propaganda, Clinton & Trump
Andrew Levine
The Hillary Era is Coming: Worry!
Gary Leupp
Seven World-Historical Achievements of the Iraq Invasion of 2003
Paul Street
Standing Rock Water-Protectors Waterboarded While the Cleveland Indians Romped
Stanley L. Cohen
Israel: 1984 Everlasting
Michael Brenner
American Foreign Policy in the Post-Trump Era
Luciana Bohne
Crossing the Acheron: Back to Vietnam
Robert Hunziker
The Political Era of Climate Refugees
Stephen Cooper
Alabama’s Last Execution was an Atrocity
Pete Dolack
Work Harder So Speculators Can Get More
Joyce Nelson
Canadians Launch Constitutional Challenge Against CETA
John Laforge
US Uranium Weapons Have Been Used in Syria
Paul Edwards
The Vision Thing ’16
Arshad Khan
Hillary, Trump and Sartre: How Existentialism Disrobes the Major Presidential Candidates
Peter Lee
It’s ON! Between Duterte and America
Joseph Grosso
Starchitects in the City: Vanity Fair and Gentrification
Patrick Carr
Economic Racial Disparity in North Carolina
David Swanson
Public vs. Media on War
Chris Gilbert
Demo Derby in Venezuela: The Left’s New Freewheeling Politics
Binoy Kampmark
Nobel Confusion: Ramos-Horta, Trump and World Disorder
Stephen Cooper
Alabama’s Last Execution Was an Atrocity
Binoy Kampmark
Nobel Confusion: Ramos-Horta, Trump and World Disorder
Russell Mokhiber
Lucifer’s Banker: Bradley Birkenfeld on Corporate Crime in America
Ron Jacobs
Death to the Fascist Insect! The SLA and the Cops
Cesar Chelala
Embargo on Cuba is an Embarrassment for the United States
Jack Smith
And the Winner Is….
Ken Knabb
Beyond Voting: the Limits of Electoral Politics
Matt Peppe
An Alternate Narrative on Hillary Clinton and Donald Trump
James Rothenberg
Water Under the Bridge
Louis Yako
Remembering Rasul Gamzatov: The Poet of the People
Brian Cloughley
The US, NATO and the Pope
Louis Proyect
The Outsider-Insider: Isaac Babel’s Big Mistake
Martin Billheimer
Now and Then, Ancient Sorceries
October 27, 2016
Paul Street
An Identity-Politicized Election and World Series Lakefront Liberals Can Love
Matthew Stevenson
Sex and the Presidential City
Jim Kavanagh
Tom Hayden’s Haunting
CJ Hopkins
The Pathologization of Dissent
Mike Merryman-Lotze
The Inherent Violence of Israel’s Gaza Blockade
Robert Fisk
Is Yemen Too Much for the World to Take?
Shamus Cooke
Stopping Hillary’s Coming War on Syria
Jan Oberg
Security Politics and the Closing of the Open Society
Ramzy Baroud
The War on UNESCO: Al-Aqsa Mosque is Palestinian and East Jerusalem is Illegally Occupied
Colin Todhunter
Lower Yields and Agropoisons: What is the Point of GM Mustard in India?
Norman Pollack
The Election: Does It Matter Who Wins?
Nyla Ali Khan
The Political and Cultural Richness of Kashmiriyat